Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations

[1]  N. Normanno,et al.  The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC. , 2021, Lung cancer.

[2]  T. Owonikoko,et al.  Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib , 2021, Cancer Research.

[3]  S. Cedrés,et al.  Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. , 2020, Clinical lung cancer.

[4]  R. Jiang,et al.  Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations , 2020, Frontiers in Oncology.

[5]  A. Mansfield,et al.  Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. , 2020, Lung cancer.

[6]  R. Jiang,et al.  Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid , 2019, Front. Oncol..

[7]  M. Tiseo,et al.  From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. , 2019, Lung cancer.

[8]  Xue Wu,et al.  Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. , 2018, Lung cancer.

[9]  Young Hak Kim,et al.  Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer , 2016, Molecular Cancer Therapeutics.

[10]  C. Rudin,et al.  Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. , 2015, Cancer cell.

[11]  A. Shaw,et al.  Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Gajra,et al.  Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291) , 2017, OncoTargets and therapy.